Ensysce Biosciences, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 7946 IVANHOE AVENUE, LA JOLLA, CA, 92037
Mailing Address 7946 IVANHOE AVENUE, LA JOLLA, CA, 92037
Phone (858) 263-4196
Fiscal Year End 1231
EIN 822755287
Financial Overview
FY2025
$4.57M
Total Liabilities
$4.31M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| 8-K Current report of material events | February 27, 2026 | View on SEC |
| 8-K Current report of material events | January 8, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | December 2, 2025 | View on SEC |
| DEF 14A Definitive proxy statement | December 2, 2025 | View on SEC |
| 8-K Current report of material events | November 17, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 14, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Proprietary TAAP and MPAR platforms designed to create safer, abuse-deterrent pain medications.
- Advancing lead clinical-stage candidates PF614 and PF614-MPAR through Phase 3 trials.
Material Events
8-K Financial Distress February 27, 2026
High Impact
- Dedicated to developing abuse-deterrent pain medications, addressing a critical market need.
- Advancing lead drug candidates PF614 and PF6100 through its development pipeline.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.